Turn Therapeutics Inc. (TTRX) Financial Ratios
2 years of historical data (2023–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
ROE
N/A
—
5yr avg: -2672.6%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TTRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Market Cap | $112M | — | — |
| Enterprise Value | $111M | — | — |
| P/E Ratio → | — | — | — |
| P/S Ratio | — | — | — |
| P/B Ratio | — | — | — |
| P/FCF | — | — | — |
| P/OCF | — | — | — |
P/E links to full P/E history page with 30-year chart
TTRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| EV / Revenue | — | — | — |
| EV / EBITDA | — | — | — |
| EV / EBIT | — | — | — |
| EV / FCF | — | — | — |
TTRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Gross Margin | — | — | — |
| Operating Margin | — | — | — |
| Net Profit Margin | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| ROE | — | — | -2672.6% |
| ROA | -87.1% | -87.1% | -113.8% |
| ROIC | — | — | — |
| ROCE | -125.5% | -125.5% | -151.5% |
TTRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $872599 exceeds total debt of $121036, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Debt / Equity | — | — | 0.29 |
| Debt / EBITDA | — | — | — |
| Net Debt / Equity | — | — | -13.48 |
| Net Debt / EBITDA | — | — | — |
| Debt / FCF | — | — | — |
| Interest Coverage | — | — | — |
Net cash position: cash ($872599) exceeds total debt ($121036)
TTRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.55x means Turn Therapeutics Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.45x to 1.55x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Current Ratio | 1.55 | 1.55 | 2.45 |
| Quick Ratio | 1.55 | 1.55 | 2.45 |
| Cash Ratio | 1.23 | 1.23 | 2.41 |
| Asset Turnover | — | — | — |
| Inventory Turnover | — | — | — |
| Days Sales Outstanding | — | — | — |
TTRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Turn Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Dividend Yield | — | — | — |
| Payout Ratio | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Earnings Yield | — | — | — |
| FCF Yield | — | — | — |
| Buyback Yield | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | — | — |
| Shares Outstanding | — | $0 | $0 |
Peer Comparison
Compare TTRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TTRXYou | $112M | — | — | — | — | — | — | — | — |
 RCUS | $3B | -7.7 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 IMVT | $6B | -10.6 | — | — | — | — | -62.5% | — | — |
 ARQT | $3B | -162.8 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 KYMR | $7B | -23.3 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 PRAX | $10B | -24.5 | — | — | — | — | -45.8% | -65.0% | — |
 RVMD | $30B | -23.8 | — | — | — | — | -58.1% | -54.3% | — |
 VRTX | $109B | 28.1 | 21.8 | 34.2 | 85.0% | 39.4% | 22.5% | 23.0% | 0.8 |
 REGN | $74B | 17.2 | 17.9 | 18.2 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ABBV | $356B | 85.0 | 14.9 | 20.0 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 2 years · Updated daily
See TTRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TTRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TTRX vs RCUS
Side-by-side business, growth, and profitability comparison vs Arcus Biosciences, Inc..
Start ComparisonTTRX — Frequently Asked Questions
Quick answers to the most common questions about buying TTRX stock.
Is TTRX stock overvalued?
Based on historical data, Turn Therapeutics Inc. is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.